Real-world Study of Inetetamab in HER2-positive Metastatic Breast Cancer
A multicenter real-world study was conducted to gather clinicopathological data from patients with HER2-positive metastatic breast cancer who were treated with inetetamab between 2022 and 2023. The study aimed to estimate the progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and adverse events (AEs) associated with inetetamab therapy.
HER2-positive Metastatic Breast Cancer
DRUG: inetetamab
Progression Free Survival(PFS), 12 months
objective response rate (ORR), 12 months|Adverse events (AEs), 12 months
A multicenter real-world study was conducted to gather clinicopathological data from patients with HER2-positive metastatic breast cancer who were treated with inetetamab between 2022 and 2023. The study aimed to estimate the progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and adverse events (AEs) associated with inetetamab therapy.